"uuid:ID","description","name","instanceType","id","text","label"
"a0fcc73a-e21a-4db6-9685-0280660f3a10","Main objective","OBJ1","Objective","Objective_1","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).",""
"4a81ff5d-7d2a-43e8-b9f1-d32984e9b8fc","Safety","OBJ2","Objective","Objective_2","To document the safety profile of the xanomeline TTS.",""
"d3ce3aa3-adc9-49a1-8ccd-47c81f8d2199","Behaviour","OBJ3","Objective","Objective_3","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.",""
"8a7ae810-d58a-4e66-b0a9-a0031ba37afc","","OBJ4","Objective","Objective_4","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).",""
"9bd66e29-8399-404b-8d71-586bef8a690a","","OBJ5","Objective","Objective_5","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).",""
"38b31505-34fe-410a-a473-035f9052008e","","OBJ6","Objective","Objective_6","To assess the treatment response as a function of Apo E genotype.",""
